Intellia Therapeutics (NTLA)

Executive Summary

Intellia Therapeutics is a clinical-stage biotechnology company leading the development of CRISPR/Cas9-based genome editing therapies. The company's proprietary in vivo and ex vivo platforms aim to provide durable, potentially curative treatments for genetic diseases, oncology, and autoimmune conditions. Intellia's lead product, NTLA-2002, targets hereditary angioedema (HAE) and is currently in a Phase 3 trial (NCT06634420) initiated in January 2025, with data readout expected in 2027. NTLA-2001, for transthyretin amyloidosis (ATTR), completed Phase 1 with positive safety and efficacy results, supporting advancement to pivotal studies. The company also explores ex vivo editing for oncology. Despite the withdrawal of NTLA-3001 for alpha-1 antitrypsin deficiency, Intellia's robust pipeline and platform versatility position it as a leader in the gene editing space. With strong financial backing and strategic partnerships, Intellia is poised to achieve key regulatory and clinical milestones in the near term.

Upcoming Catalysts (preview)

• H2 2026NTLA-2002 Phase 3 interim efficacy and safety data for HAE75% success
• H1 2026Initiation of pivotal trial for NTLA-2001 in ATTR cardiomyopathy80% success
• 2026Partnership or licensing deal for ex vivo CRISPR programs60% success